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Aims A better understanding of the pathways that regulate regeneration of the coronary vasculature is of fundamental import-
ance for the advancement of strategies to treat patients with heart disease. Here, we aimed to investigate the origin and
clonal dynamics of endothelial cells (ECs) associated with neovascularization in the adult mouse heart following myocar-
dial infarction (MI). Furthermore, we sought to define murine cardiac endothelial heterogeneity and to characterize the
transcriptional profiles of pro-angiogenic resident ECs in the adult mouse heart, at single-cell resolution.
...................................................................................................................................................................................................
Methods
and results
An EC-specific multispectral lineage-tracing mouse (Pdgfb-iCreERT2-R26R-Brainbow2.1) was used to demonstrate
that structural integrity of adult cardiac endothelium following MI was maintained through clonal proliferation by
resident ECs in the infarct border region, without significant contributions from bone marrow cells or endothelial-
to-mesenchymal transition. Ten transcriptionally discrete heterogeneous EC states, as well as the pathways through
which each endothelial state is likely to enhance neovasculogenesis and tissue regeneration following ischaemic in-
jury were defined. Plasmalemma vesicle-associated protein (Plvap) was selected for further study, which showed an
endothelial-specific and increased expression in both the ischaemic mouse and human heart, and played a direct
role in regulating human endothelial proliferation in vitro.
...................................................................................................................................................................................................
Conclusion We present a single-cell gene expression atlas of cardiac specific resident ECs, and the transcriptional hierarchy
underpinning endogenous vascular repair following MI. These data provide a rich resource that could assist in the
development of new therapeutic interventions to augment endogenous myocardial perfusion and enhance regener-
ation in the injured heart.
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Introduction
Chronic heart failure as a consequence of left ventricular impairment
following acute myocardial infarction (MI) has reached epidemic pro-
portions affecting more than 23 million patients worldwide.1–4
Patients have a poor prognosis with a mortality of 45–60% by
5 years.5 Early reperfusion following MI is important to limit infarct
size, however, patients who present late with extensive myocardial
injury benefit little from these treatments. In this high-risk group, new
therapeutic approaches are required to enhance myocardial perfu-
sion, limit infarct expansion, and promote cardiac repair and regener-
ation. As such, extensive research has focused on harnessing the
regenerative value of exogenous cell transplantation, and on elucidat-
ing the endogenous mechanisms that promote structural repair in
the injured heart.
Experimental studies have produced disparate results regarding
the regenerative potential of transplanted bone marrow cells in the
setting of MI, including their contribution to vascular structures in vivo
(reviewed in Refs6,7). Moreover, clinical trials using autologous bone
marrow-derived cell transplantation aimed at promoting recovery
following acute MI have largely failed to show sustained clinical ben-
efit.6,8 Recently, endothelial cell (EC) clonal expansion in the post-
ischaemic myocardium was shown using a Cdh5-CreERT2 lineage-
tracing mouse.9 However, Cre-recombinase can be detected in bone
marrow cells as well as endothelium in Cdh5-Cre lines and therefore
the origin of these proliferative EC remains somewhat inconclusive.10
In the same study, clonally expanded EC co-expressed endothelial
and mesenchymal markers, leading to the conjecture that ‘partial’
endothelial-to-mesenchymal transition (EndMT) may be associated
with new vessel growth post-MI.9 However, a direct role for EndMT
in therapeutic angiogenesis has not been conclusively shown, to date.
Therefore, the cellular origin and mechanisms of neovascularization
following MI remain unresolved, including whether reparative EC de-
rive from a bone marrow niche or reside locally within the cardiac
microvasculature.
Here, we have used an EC-specific multispectral lineage-tracing
mouse (Pdgfb-iCreERT2-R26R-Brainbow2.1) coupled with single-cell
RNA sequencing to collectively investigate the origin, proliferative
dynamics and transcriptional profile of EC that mediate neovasculo-
genesis in the adult mouse heart. We show that a subpopulation of
resident EC with progenitor-like functional properties directly con-
tribute to new blood vessel formation at 7 days following MI, with
evidence that bone marrow-derived cells and EndMT are unlikely to
contribute. We have identified multiple discrete heterogeneous EC
states in the healthy and post-ischaemic heart, and characterized
gene expression profiles of each EC state at the single-cell level.
These data identified plasmalemma vesicle-associated protein (Plvap)
as a novel endothelial-specific marker of cardiac neovasculogenesis,
which was further validated in cardiac samples from patients with is-
chaemic heart disease and following gene silencing in vitro. Together,
these data provide a comprehensive single-cell index of gene expres-
sion by resident cardiac EC that contribute to endogenous
neovascularization in the infarcted myocardium and will assist identifi-
cation of new therapeutic targets for heart disease.
Methods
See Supplementary material online for extended experimental
procedures.
Results
Brainbow2.1 (Confetti) reporter
fluorophore expression is specific to
endothelial cells in adult Pdgfb-iCreERT2-
R26R-Brainbow2.1mouse hearts
We first evaluated Pdgfb expression in the adult mouse coronary vas-
culature, which has not been widely characterized. We used the
presence of a sequence coding for enhanced green fluorescent pro-
tein (EGFP) located downstream of iCreERT2 in Pdgfb-iCreERT2 mice11
(Figure 1A, Supplementary material online, Figure S1A–C) to show that
Pdgfb-EGFP expression was widespread and endothelial-specific, con-
firmed by co-localization of EGFP with isolectin B4 (Figure 1B). We
further showed using flow cytometry that Pdgfb was expressed by
94.5 ± 5.6% of CD31þ vascular EC in the adult Pdgfb-iCreERT2-R26R-
Brainbow2.1 mouse heart (Supplementary material online, Figure
S1C). Expression of the four fluorophores encoded by the
Brainbow2.1 transgene (YFP, RFP, nGFP, mCFP) was specific to Pdgfb-
EGFPþ cells (Figures 1C; Supplementary material online, Figure S1D
and E). Cre-recombination efficiency was 46.6 (±9.3) % of total car-
diac Pdgfb-EGFPþ cells, and no reporter expression was observed in
mice administered peanut oil as a vehicle control for tamoxifen or in
Cre-negative mice administered tamoxifen (Supplementary material
online, Figure S1D–G).
Translational perspective
Chronic heart failure following acute myocardial infarction (MI) has reached global epidemic proportions, and new therapeutic
approaches are vital. Functional neovascularization in the infarct border may delay progression to heart failure and improve outcome,
although the underpinning mechanisms remain unclear. We show that resident cardiac endothelial cells (ECs), and not bone marrow
cells, mediate therapeutic angiogenesis post-MI, and provide a unique single-cell atlas of the transcriptional signature of these regenera-
tive cardiac EC. We predict that these data will inform future design of clinical strategies aimed at promoting vascular perfusion and
long-term functional viability of the ischaemic heart.
2508 Z. Li et al.
Figure 1 Genetic labelling strategy used for study of Pdgfb-iCreERT2 expressing endothelial cells using the R26R-Brainbow2.1 ‘Confetti’ reporter
mouse (A). Tamoxifen was administered by intraperitoneal injection followed by coronary artery ligation 14 days later. Injured and healthy hearts)
were collected 7 days post-surgery to quantify clonal proliferation and bone marrow reporter expression, or for single-cell RNA sequencing
(scRNA-seq) of vascular cardiac Pdgfb-lineage endothelial cells (CD31þ podoplanin- Confettiþ) (A). Isolectin B4 (IB4) was injected intravenously
15 min prior to cull to identify perfused vessels in the vasculature of Pdgfb-iCreERT2-R26R-Brainbow2.1 adult mouse hearts. Co-expression of isolectin
B4 (IB4, red) with Pdgfb-EGFP endothelial cells (green, with co-localized expression shown in orange) demonstrated widespread patency in vessels
formed by Pdgfb-lineage endothelial cell clonal proliferation (B). Masson’s trichrome staining confirmed healthy myocardial tissue or the presence of
an infarct in each group (C). Clonal proliferation was quantified in 100lm tissue wholemounts in the infarct border and equivalent healthy region,
where a clone was defined as two or more adjacent cells expressing YFP, RFP, nGFP, or mCFP. Clones of each colour were observed throughout
the healthy heart with a significant increase in fluorophore expression and clone size in the infarcted (MI) hearts (cells per clone = 4.0 ± 2.1 vs.
10.3± 10.6, P < 0.0001) (C, D). Clones of >50 cells were commonly observed in the infarct border (E; 2 large multicellular clones in the infarct border
expressing RFP or YFP). Vessels with a polychromatic endothelium were observed in healthy and infarcted hearts but were significantly less abundant
than monoclonal vessels in both groups (healthy hearts = 25.5 ± 4.1% vs. 74.5 ± 4.1%, P < 0.001; MI hearts = 9.3 ± 15.3% vs. 90.7± 15.3%, P < 0.001)
(F; with arrows showing contiguous vessels composed of Pdgfb-lineage endothelial cells expressing different Confetti reporter fluorophores in the in-
farct border).
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Cardiac Pdgfb-lineage endothelial cells
undergo clonal proliferation to form
new perfused blood vessels following
myocardial infarction
Clonal proliferation by EC was observed in the healthy heart at
21 days post-tamoxifen, highlighting that Pdgfb-lineage cardiac EC are
not quiescent in physiological conditions (Figure 1C). Clone size was
significantly increased in the infarct border region at 7 days post-MI,
with clones of >50 cells frequently present (cells per clone =
4.0± 2.1 vs. 10.3± 10.6, P < 0.0001; Figure 1C–E; Supplementary ma-
terial online, Movie S1). Representative histological images of injured
and healthy hearts are shown in Supplementary material online,
Figure S2. Perfusion of vessels formed by clonal proliferation of Pdgfb-
EC was confirmed by fluorophore co-expression with isolectin-B4,
infused intravenously just prior to cull (Figure 1B). Consistent with
other studies using the R26R-Brainbow2.1 mouse,12 we observed a
bias in fluorophore distribution in both groups with YFP, RFP, nGFP,
and mCFP expressed by 51.9± 13.5, 25.7± 8.7, 11.3± 6.2, and
11.8 ± 5.8% of total reporter expressing cells in the healthy heart, and
Figure 2 A complete transverse section of the left ventricle at 7 days post-MI showing increased density of EdU expressing cells in the border re-
gion compared with the infarct and remote region (A). Dense neovascularization due to clonal proliferation of Pdgfb-lineage endothelial cells was
observed in the infarct border region (B, with high power inserts in C–E). Confettiþ Pdgfb-lineage endothelial cells frequently co-expressed EdU (B–
E) and were significantly increased in the infarct border at 7 days post-MI compared with the Confettiþ EdUþ Pdgfb-lineage endothelial cells in the
left ventricle of healthy uninjured mice (28.5 ± 4.8% vs. 58.5 ± 7.6%, P = 0.0005) (F). Representative flow cytometry plots showing very low reporter
fluorophore expression in femoral bone marrow cells from adult Pdgfb-iCreERT2-R26R-Brainbow2.1 mice are shown in (G) with threshold gates set for
each fluorophore using C57Bl6 wild type mice bone marrow cells as a negative control. No change in fluorophore expression by bone marrow cells
was observed between healthy and MI groups (0.04 ± 0.02% vs. 0.03± 0.009%, P = 0.79) (H). The founding number of recombined events (where a
Confettiþ cell or clone was counted as one event) was unchanged between healthy and MI groups (72.3 ± 9.0 vs. 67.3 ± 6.6 events per section,
P = 0.46) (I).
2510 Z. Li et al.
Figure 3 Ten discrete heterogeneous endothelial cell populations were identified in healthy and infarcted adult mouse hearts (A and B).
Contributions of cells from both healthy and myocardial infarction hearts to each cluster were compared, and cluster 2, 3, 6, 8, and 10 were largely
constituted by the cells from the myocardial infarction hearts. Cluster 7 was composed exclusively of cells from the myocardial infarction hearts (C).
Broad expression of endothelial cell markers, such as Pecam1 and Kdr, and the rare presence of Pdpn and Ptprc expressing cells showed purity of the
studied endothelial cell population (D). Top differentially expressed marker genes were shown for each of the 10 clusters in the heatmap (E).
Single cell transcriptome analyses of cardiac endothelial cells 2511
Figure 4 Rare Ptprcþ (CD45) cells that co-expressed high levels of Pecam-1 (0.29% total cells) or KDR (0.19% total cells) were dispersed through-
out several clusters in the MI group (A). Cells that co-expressed CD45 and a Confetti reporter fluorophore were observed at the infarct border in
100lm tissue wholemounts (B, arrows). Cluster 3 showed co-expression of endothelial markers, Pecam-1 and Kdr, with genes encoding cardiac
muscle markers including troponin-T (Tnnt2) (C). Cells that co-expressed a Brainbow2.1 fluorophore and the cardiomyocyte marker, troponin-T,
were identified in the infarct border region in 100lm tissue wholemounts (D, arrows). These cells were scarce and resembled vascular structures in
morphology, rather than cardiomyocytes.
2512 Z. Li et al.
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by 52.9 ± 26.5, 18.8± 15.0, 26.5 ± 29.8, and 8.8± 7.8% of total report-
er expressing cells in the injured heart (Supplementary material on-
line, Figure S1H and I). However, clone size did not differ between
each fluorophore in either group (Supplementary material online,
Figure S1J and K). Therefore, patches were likely to be formed
through clonal expansion, and not by the merger of multiple smaller
clones of the same colour (see Supplementary material online file for
detailed methods used for quantitative analysis of clonal
proliferation).
Vessels with a polychromatic endothelium were frequently
observed in healthy and infarcted hearts and most likely repre-
sented pre-existing vessels composed of labelled EC that had not
undergone proliferation within the study timeframe, or new ves-
sels formed from the merger of non-proliferative labelled EC
(Figure 1F). Polychromatic vessels were significantly less abundant
than monoclonal vessels in both groups (healthy hearts =
25.5± 4.1% vs. 74.5 ± 4.1%, P < 0.001; MI hearts = 9.3 ± 15.3% vs.
90.7± 15.3%, P < 0.001), implying that clonal proliferation is a
dominant mechanism of cardiac EC turnover in homeostasis and
in response to injury. The proportion of Confettiþ EC present as
single cells, i.e. that had not undergone division during the preced-
ing 21 days, was similar in healthy and MI groups (54.6 ± 6.6% vs.
63.4± 4.7%, P = 0.28). Therefore, vascular turnover and
neovascularization by clonal proliferation appears be restricted to
a subpopulation of Pdgfb-lineage EC, presumably with progenitor-
like properties. The thymidine analogue 5-ethynyl-20-deoxyuridine
(EdU) was administered 1 h prior to cull to label cells in S phase.
EdUþ total cardiac cells were significantly increased in the infarct
border at 7 days post-MI compared with the healthy left ventricle,
as expected (0.09± 0.04% vs. 1.9 ± 0.6%, P < 0.0001). The percent-
age of Confettiþ EC that co-expressed EdU was also increased in
the infarct border compared with the healthy left ventricle
(28.5± 4.8% vs. 58.5± 7.6%, P = 0.0005), underlining our evidence
that the infarct border is a region of dense neovasculogenesis
with maximal clonal proliferation by Pdgfb-EC (Figure 2A–F).
Brainbow2.1 reporter fluorophore
expression is minimal in bone marrow
cells in Pdgfb-iCreERT2-R26R-Brainbow2.1
mice
We observed minimal Brainbow2.1 reporter expression in femoral
bone marrow cells in healthy and MI groups (0.04 ± 0.02% vs.
0.03± 0.009%, P = 0.79) (Figure 2F and G). Therefore, we postulated
that Pdgfb-lineage EC reside locally within the cardiac vasculature.
This was corroborated by our observation that the founding number
of recombined events (i.e. a Confettiþ cell or clone) did not differ sig-
nificantly between groups (P = 0.46) (Figure 2H) and thus migration of
Pdgfb-lineage Brainbow2.1 fluorophore expressing EC from outside
the heart was likely to be rare.
Single-cell RNA sequencing defines
the transcriptional signature of 10
heterogeneous cardiac endothelial cell
states in the adult mouse heart
Pdgfb-lineage vascular EC (Confettiþ CD31þ podoplanin) were
isolated as single cells from dissociated ventricles of healthy and
ischaemic hearts at 7 days post-MI for single-cell RNA sequencing
(Supplementary material online, Figure S3A). Mean 3195 (range
2637–3535) and 3955 (range 3326–4744) cells were retained for
analysis from the healthy and MI groups, respectively (P = 0.11)
after filtering of cells with a low gene count (<400 genes per cell)
and a high mitochondrial transcript ratio (threshold of 20%)
(Supplementary material online, Figure S3B). Mean number of
unique molecular identifiers (UMIs) was 2232 (range 2035–2398)
and 5041 (range 4165–5604) (P = 0.03), and median gene number
per cell was 1180 (range 1046–1217) and 2133 (range 1807–2251)
(P = 0.03) for the healthy and MI groups (Supplementary material
online, Figure S3B). Dimension reduction by principal component
analysis of the whole transcriptome gene signature followed by 3D
t-distributed stochastic neighbour embedding (t-SNE) projection
assigned cells into 10 transcriptionally distinct clusters, i.e. discrete
heterogeneous EC states (Figure 3A). Cluster distributions were
conserved in each biological replicate animal in each group
(Supplementary material online, Figure S3C). The proportion of
cells in each cluster, the contribution of cells from both groups to
individual clusters, as well as a heat map of top differentially
expressed genes in each cluster are shown in Figure 3B, C, and E.
An isolated cluster of cells that expressed the haematopoietic
marker Ptprc (CD45) but did not express endothelial markers
Pecam-1 (CD31) or Kdr (VEGFR2) was removed from the analysis,
as it was likely due to cellular contamination during FACS.
Following this, we confirmed enrichment of Pecam-1 and Kdr in all
clusters and a minimal presence of lymphatic markers in our ana-
lysis (Figure 3D). A very small proportion of Ptprcþ cells from the
MI group that co-expressed Pecam-1 (0.29% total cells) or KDR
(0.19% total cells) was dispersed throughout several clusters
(Figure 4A). Correspondingly, we observed rare in situ expression
of CD45 by Pdgfb-lineage EC post-MI (Figure 4B). These CD45þ
cells may be EC that have transitioned towards an inflammatory
phenotype in response to injury or, more likely, scarce infiltrating
bone marrow cells, described above.
We used Gene Ontology (GO) term enrichment analysis
(PANTHER, GOrilla and GeneMANIA) to reveal significant terms
associated with the top differentially expressed genes in each cluster,
which allowed us to extrapolate information regarding the functional
identity of each EC state (Table 1). For example, cluster 10 predomin-
antly comprised cells from the MI group with a high and restricted ex-
pression of cell cycle and proliferation markers (e.g. Mki67, Top2a,
Cenpf, Cks2, Birc5, Cenpa, Ube2c, Cdc2029,30). Our aforementioned
observations of heightened clonal proliferation post-MI by Pdgfb-lin-
eage EC compared with the healthy heart, substantiated this gene ex-
pression profile (Figure 1D). Cluster 3 showed selective expression of
genes encoding ventricular cardiac muscle morphogenesis (Myl2, Mb,
Myl3, Tnnt2, Tnni3, Actc1), suggesting that resident adult cardiac EC
may switch on cardiomyocyte lineage genes in response to MI. This
was supported by a study showing cardiac muscle cells derived from
embryonic EC following their direct injection into the ischaemic adult
mouse heart.19 We confirmed rare in situ existence of cells that co-
expressed a Brainbow2.1 fluorophore and the cardiomyocyte marker,
troponin-T, in the infarct border region, but not in the healthy heart
(Figure 4C and D). Therefore, an endothelial to cardiomyocyte fate
shift may occur post-MI, although did not contribute significantly to
myocardial regeneration at the studied timepoint.
Single cell transcriptome analyses of cardiac endothelial cells 2513
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Endothelial-to-mesenchymal transition
does not contribute to cardiac
neovasculogenesis at 7 days post-
myocardial infarction
Endothelial markers were not reduced after MI in our data (Figure
3D), and therefore, we investigated the role of ‘partial EndMT’, re-
cently hypothesized to play a role in neovascularization in the ischae-
mic mouse heart.9 However, the overall EndMT signature was
unchanged in both groups (Figure 5A and B) despite an increase in
some EndMT markers after MI (Icam1, Vcam1, Vim, Fn1 and Smtn)
(Figure 5C). This indicates that EndMT and partial EndMT are unlikely
to participate significantly in our model at the studied timepoint.
Plasmalemma vesicle-associated protein
represents a novel potential therapeutic
target that mediates neovasculogenesis
in the ischaemic mouse and human heart
Clusters 6, 7, and 8 predominantly comprised cells from the MI group
(Figure 3B), indicating that their gene expression profiles may be rele-
vant to neovasculogenic pathways. Gene expression of Plvap was
....................................................................................................................................................................................................................
Table 1 Top differentially expressed markers and predicted functions of each cluster
Cluster
number
Enrichment in EC
from healthy or
MI groups
Top differentially
expressed genes
Specific to
cluster
Predicted func-
tion in Pdgfb-EC
References to support pre-
dicted function
1 NA (P = 0.34) Arhgap18, Adm, Hspb1,
CD36
N Cellular homeostasis (13–16)
2 MI (P = 0.02) Ifit1, Ifit2, Ifit3, Ifit3b,
Usp18, Cxcl10
Y Interferon signalling (17) IFN signalling in CVD including
MI; (18) Induction of EC prolifer-
ation by IFN
3 MI (P = 0.0006) Myl2, Mb, Myl3, Tnnt2,
Tnni3, Actc1
Y Ventricular cardiac
muscle remodelling
(19) Embryonic EC trans-differenti-
ation to cardiac muscle cells in MI
4 NA (P = 0.07) Klra3, Klra9, Klra10 Y Killer cell lectin-like
receptor signalling
(20) NK cell interaction with EC
driving neovasculogenesis post-
MI; (21) EC expression of Klra
family genes; (22) CD31 expres-
sion by NK cells
5 NA (P = 0.51) Dll4, Notch1, Hey1,
Jag1, Gja4
Y (Hey1, Jag1,
Gja4)
Endothelial cell regula-
tion via Notch
signalling
(23) Notch regulation of EC; (24,25)
Gja4 encodes Connexin37 in EC,
which regulates arterial-venous
specification; (26) Gja4-deficient
mice have abnormal vascular re-
generation in ischaemic limb
6 MI (P = 0.006) Plvap, Lrg1, Pbp1, Bgn,
vWF
N Ventricular remodel-
ling [via retinoic
acid (RA) signalling]
(27,28) Regulation of ventricular
remodelling by Rbp1 and Bgn via
RA signalling post-MI
7 MI (100%) Ackr1, Ehd4,
Tmem176a,
Tmem252,
Tmem176b, Selp
Y (Ackr1,
Tmem252,
Selp)
Stalk cell markers. Tip
and stalk cell-medi-
ated
neovasculogenesis
(29,30) EC tip and stalk cell signalling;
(31) Fate switching between tip
and stalk cells, enhanced prolifer-
ation by stalk versus tip cells
8 MI (P = 0.07) Fbln2, Anxa2, Col5a2,
Emilin1, Hmcn1, Bgn,
Mgp
Y (Col5a2,
Mgp)
Endothelial ECM pro-
teins, cardiac
remodelling post-
MI
(32) Cardiac remodelling in human
and pigs post-MI; (33) Endothelial
ECM critical for blood vessel net-
work stabilization and maturation
9 NA (P = 0.69) Serpina1b, Serpina1d,
Serpina1e
Y Serine protease inhibi-
tor alpha-1 anti-
trypsin (AAT)
signalling
(34,35) AAT therapy in ischaemic dis-
ease; (36,37) AAT is cytoprotective
following ischaemic injury
10 MI (P = 0.02) Mki67, Top2a, Cenpf,
Cks2, Birc5, Cenpa,
Ube2c, Cdc20
Y Proliferation and cell
cycle regulation
(38)
2514 Z. Li et al.
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..highest in clusters 6, 7, and 8 (Figure 6A and B). Plasmalemma vesicle-
associated protein encodes an EC-specific marker,39 although its role
in neovasculogenesis in the adult heart is unknown. We quantified
Plvap expression in the healthy and infarcted mouse heart, as well as
in healthy and ischaemic human cardiac tissue sections. Plvap expres-
sion was specific to CD31þ EC and was increased in the infarct
border compared with the healthy left ventricle, thus validating our
RNA sequencing data at the protein level (% Plvapþ EC =
70.5 ± 19.9% vs. 38.7± 28.2%, P = 0.002, Figure 6C, E–G). Plvap ex-
pression was also increased in EC adjacent to regions of fibrosis and
scarring in the ischaemic human heart, compared with healthy human
hearts (% Plvapþ EC = 36.9 ± 10.1% vs. 11.1 ± 8.8%, P = 0.002, Figure
Figure 5 Endothelial-to-mesenchymal transition/partial endothelial-to-mesenchymal transition was investigated in our data using a comprehensive
panel of markers of early and late endothelial-to-mesenchymal transition (A). The change in an endothelial-to-mesenchymal transition gene signature
between healthy and myocardial infarction groups was minimal and not specific to any cluster (B) despite an increase in some markers (C).
Single cell transcriptome analyses of cardiac endothelial cells 2515
Figure 6 Violin plots showing heightened expression of Plvap in clusters 6, 7, and 8 (A). t-SNE plots highlighting an increased Plvap gene expression
in cardiac endothelial cells from the myocardial infarction group compared with the healthy group (B). Plvap was significantly increased in the infarct
(continued)
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.6D, H–O). In order to better understand whether Plvap can directly
modulate neovascularization we carried out in vitro siRNA gene
silencing on human umbilical venous EC (HUVEC) where Plvap ex-
pression was significantly reduced at the mRNA level compared with
control siRNA (RQ = 3.0 ± 0.9 vs. 0.2 ± 0.2, P = 0.003) and confirmed
at the protein level by western blot (Figure 6P, S). Proliferation was
assessed using an EdU incorporation assay and was significantly inhib-
ited following Plvap gene silencing compared with control siRNA
treatment (% EdUþ HUVEC = 60.7± 3.9% vs. 21.1± 11.0%,
P = 0.0038; Figure 6Q and R), providing strong evidence for a direct
functional role of PLVAP in endothelial proliferation.
Discussion
In this study, we demonstrate that structural integrity of the endothe-
lium of the adult heart during physiological conditions and following
MI is maintained through clonal proliferation of a subset of resident
EC with progenitor-like functional properties with minimal, if any,
contribution by bone marrow cells. We further present the first
comprehensive single-cell atlas of gene expression by 10 individual
EC subpopulations in the adult mouse heart after MI. Finally, we
show that Plvap is likely to represent a novel target to augment new
vessel formation in the ischaemic human heart.
Our observation that clonal expansion of resident cardiac EC is
the predominant mechanism driving neovasculogenesis expand on
recent findings of He et al.40 who used genetic lineage tracing to
show that new cardiac blood vessels are formed from pre-existing
EC. This may, in part, explain the disappointing outcomes of clinical
studies using autologous bone marrow-derived cells for therapeutic
neovascularization in patients with ischaemic heart disease.6,8 It is im-
portant to note that a contribution of Pdgfb-lineage EC to cardiac
neovasculogenesis post-MI cannot be discounted, i.e. due to an in-
active Cre-driver or the migration of non-recombined cells.
However, despite a 46.6% Cre-recombination efficiency in cardiac
ECs we observed Brainbow2.1 reporter fluorophore expression in
fewer than 0.05% of bone marrow cells. Furthermore, the founding
number of recombined events in the cardiac vasculature did not
change before or after ischaemic injury. This led us to postulate that
Pdgfb-lineage EC contributing to neovasculogenesis via clonal
proliferation reside locally within the cardiac vasculature with min-
imal, if any, contribution from bone marrow cells. Therefore, future
research and clinical focus should aim to enhance the regenerative
capacity of endogenous resident cardiac EC to promote therapeutic
neovasculogenesis in the injured heart.
Using single-cell RNA sequencing, we have defined endothelial
heterogeneity in the healthy and injured mouse heart through
characterization of 10 EC states with distinct gene expression signa-
tures, and by mapping the transcriptional changes arising in each sub-
set following injury, at the level of a single cell. Transcriptional
profiling of the non-myocyte cardiac cellulome of healthy mice was
recently reported,41 although EC were strategically depleted prior to
sequencing to enable focused analysis of fibroblasts and rarer cardiac
lineages such as glia and mural cells. Single-cell RNA sequencing was
also recently applied to map cell populations in the healthy and
injured mouse heart 3 days after ischaemia–reperfusion surgery.42
This study identified two EC clusters, although detailed EC gene ex-
pression analysis was not provided as this study focused on changing
cardiomyocyte subpopulations. Therefore, we believe our data is the
first in-depth characterization of the molecular profiles that demar-
cate cardiac endothelial heterogeneity and plasticity in response to is-
chaemic injury.
We defined changes in EndMT gene signatures between healthy
and injured cardiac EC using a broad panel of markers.9,43 However,
as we found no inhibition of endothelial genes nor a significant change
in the EndMT gene signature, we concluded that EndMT does not
play an obvious role in our model at the timepoint studied. This con-
trasts with a recent report suggesting that partial induction of EndMT
may support cardiac neovascularization after ischaemia.9 This dis-
crepancy may be due to a transient nature of EndMT, as the authors
did not clarify whether partial EndMT genes were enriched at 7 or
14-days post-MI. Therefore, further temporal analysis of EndMT gene
signatures following injury, as well as investigation into whether
EndMT directly facilitates cardiac neovasculogenesis are warranted.
Plasmalemma vesicle-associated protein was selected for further
study, due to its cluster-restricted increase in MI, and the lack of
understanding of its role in endothelial regulation in the adult heart.
Plasmalemma vesicle-associated protein is specifically expressed by
EC and increased in some inflammatory states44 as well as in patho-
genic angiogenesis.45–47 Here, we showed increased Plvap expression
Figure 6 Continued
border region at 7 days post-myocardial infarction, compared with the healthy mouse heart (70.5 ± 19.9% vs. 38.7± 28.2%, P = 0.002) (C).
Plvap expression was also increased in endothelial cells adjacent to regions of fibrosis and scarring in the ischaemic human heart, compared
with healthy human hearts (% Plvapþ endothelial cells = 36.9 ± 10.1% vs. 11.1 ± 8.8%, P = 0.002) (D). Representative images showing immu-
nofluoresence staining for Plvap accompanying the above data showing the change in expression in cardiac endothelial cells in the healthy (E)
and injured Pdgfb-iCreERT2-R26R-Brainbow2.1 mouse heart in the infarct border at 7 days post-myocardial infarction (F), with co-expression of
Pdgfb-EC Confetti fluorophore-expressing clones (G with high power inserts and arrows highlighting Plvapþ Confettiþ EC). Consecutive sec-
tions from ischaemic and healthy human cardiac tissue were stained using Masson’s Trichrome (H = healthy, L = ischaemic) and by immuno-
fluorescence for PLVAP and CD31 (green and red, respectively, with co-expression in yellow; I–K = ischaemic, M–O = healthy). PLVAP
expression was specific to CD31þ cells and was increased in regions of fibrosis and scarring in the diseased compared with the healthy heart.
Plvapþ CD31þ vessels are indicated by yellow arrowheads (J, O), CD31þ Plvap- vessels indicated by red stars (J, N). Plvapþ CD31þ EC ex-
pression in a venule (yellow arrowhead), arteriole (yellow asterisk) and capillary (yellow star) is shown in (K). siRNA gene silencing of Plvap
in human umbilical venous endothelial cells gave a significant reduction at the mRNA level compared with control siRNA (RQ = 3.0 ± 0.9 vs.
0.2± 0.2, P = 0.003) (P) and was confirmed at the protein level by western blot (S). Proliferation assessed using an EdU incorporation assay
was significantly inhibited following Plvap gene silencing compared with control siRNA treatment (% EdUþ human umbilical venous endothe-
lial cells = 60.7 ± 3.9% vs. 21.1± 11.0%, P = 0.0038; Q, R).
Single cell transcriptome analyses of cardiac endothelial cells 2517
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..specifically within EC in clonal neovessels in the ischaemic border re-
gion of the mouse heart, and in regions of fibrosis and scarring in the
ischaemic human heart, compared with non-ischaemic hearts. We
further demonstrated that targeted silencing of Plvap in vitro directly
inhibits EC proliferation. Therefore, Plvap shows early promise as a
gene of interest for therapeutic strategies to promote cardiac regen-
eration. Future studies must now systematically evaluate the molecu-
lar pathways and regenerative significance of enhanced Plvap
expression in EC in the infarct border region at the time of injury.
However, at present, methods for cardiac endothelial-specific gene
delivery to increase expression are challenging, and therefore, genetic
mouse models and/or a pharmacological approach would be
required.
The current study provides a high-resolution single cell gene ex-
pression atlas of resident cardiac EC in both physiological conditions
and following permanent ligation of the left anterior descending
coronary artery at 7 days post-MI. This model results in massive car-
diomyocyte death, coagulative necrosis and scarring, with evidence
of significant neovasculogenesis in the infarct border region.
However, this model is unlikely to stimulate EC-mediated myocardial
regeneration, and therefore, molecular targets identified from the
analyses presented herein should be rigorously interrogated to inves-
tigate whether they promote myocardial regeneration and prevent
cardiomyocyte death through enhanced tissue perfusion, rather than
merely supporting scar formation. One could venture that a potential
limitation of this study lies within the vast wealth of data generated
from a single snap-shot in time, and care must be taken to extract
and validate future targets that most effectively tackle the clinical
problem. Therefore, consulting publicly available EC transcriptomics
data, such as the endothelial database, EndoDB,48 will assist the con-
struction of novel hypotheses for future studies.
In summary, this study provides a rich resource of targets and
pathways that can be interrogated to reveal their role in promoting
neovascularization by endogenous cardiac EC and thus may guide
novel therapeutic strategies aimed at enhancing myocardial repair
and regeneration.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Take home figure Single cell transcriptome analyses provide a single cell gene expression atlas of resident cardiac endothelial cells that pro-
mote neovascularisation following ischaemic injury by undergoing clonal proliferation.
2518 Z. Li et al.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..Declaration of Helsinki
This study was performed in accordance with the Declaration of
Helsinki.
Conflict of interest: none declared.
References
1. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present,
and future. Curr Heart Fail Rep 2014;11:404–415.
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,
Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P; Group Scientific Document Group.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure: the task force for the diagnosis and treatment of acute and chronic heart
failure of the European Society of Cardiology (ESC)Developed with the special
contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:2129–2200.
3. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD,
Group E. Fourth universal definition of myocardial infarction (2018). Eur Heart J
2019;40:237–269.
4. Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S,
Leor J, Perrino C, Schulz R, Ytrehus K, Landmesser U, Mummery CL, Janssens S,
Willerson J, Eschenhagen T, Ferdinandy P, Sluijter JP. Position Paper of the
European Society of Cardiology Working Group Cellular Biology of the Heart:
cell-based therapies for myocardial repair and regeneration in ischemic heart dis-
ease and heart failure. Eur Heart J 2016;37:1789–1798.
5. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM,
Vasan RS. Long-term trends in the incidence of and survival with heart failure. N
Engl J Med 2002;347:1397–1402.
6. Boudoulas KD, Hatzopoulos AK. Cardiac repair and regeneration: the Rubik’s
cube of cell therapy for heart disease. Dis Model Mech 2009;2:344–358.
7. Madigan M, Atoui R. Therapeutic use of stem cells for myocardial infarction.
Bioengineering (Basel) 2018;5:28.
8. Henry TD, Moye L, Traverse JH. Consistently inconsistent-bone marrow mono-
nuclear stem cell therapy following acute myocardial infarction: a decade later.
Circ Res 2016;119:404–406.
9. Manavski Y, Lucas T, Glaser SF, Dorsheimer L, Gunther S, Braun T, Rieger MA,
Zeiher AM, Boon RA, Dimmeler S. Clonal expansion of endothelial cells contrib-
utes to ischemia-induced neovascularization. Circ Res 2018;122:670–677.
10. Joseph C, Quach JM, Walkley CR, Lane SW, Lo Celso C, Purton LE. Deciphering
hematopoietic stem cells in their niches: a critical appraisal of genetic models, lin-
eage tracing, and imaging strategies. Cell Stem Cell 2013;13:520–533.
11. Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M.
Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis
2008;46:74–80.
12. Chappell J, Harman JL, Narasimhan VM, Yu H, Foote K, Simons BD, Bennett MR,
Jorgensen HF. Extensive proliferation of a subset of differentiated, yet plastic,
medial vascular smooth muscle cells contributes to neointimal formation in
mouse injury and atherosclerosis models. Circ Res 2016;119:1313–1323.
13. Lovelace MD, Powter EE, Coleman PR, Zhao Y, Parker A, Chang GH, Lay AJ,
Hunter J, McGrath AP, Jormakka M, Bertolino P, McCaughan G, Kavallaris M,
Vadas MA, Gamble JR. The RhoGAP protein ARHGAP18/SENEX localizes to
microtubules and regulates their stability in endothelial cells. Mol Biol Cell 2017;
28:1066–1078.
14. Marcovecchio PM, Thomas GD, Mikulski Z, Ehinger E, Mueller KAL, Blatchley A,
Wu R, Miller YI, Nguyen AT, Taylor AM, McNamara CA, Ley K, Hedrick CC.
Scavenger receptor CD36 directs nonclassical monocyte patrolling along the
endothelium during early atherogenesis. Arterioscler Thromb Vasc Biol 2017;37:
2043–2052.
15. Batulan Z, Pulakazhi Venu VK, Li Y, Koumbadinga G, Alvarez-Olmedo DG, Shi C,
O’Brien ER. Extracellular release and signaling by heat shock protein 27: role in
modifying vascular inflammation. Front Immunol 2016;7:285.
16. Beygui F, Wild PS, Zeller T, Germain M, Castagne R, Lackner KJ, Munzel T,
Montalescot G, Mitchell GF, Verwoert GC, Tarasov KV, Tregouet DA, Cambien
F, Blankenberg S, Tiret L. Adrenomedullin and arterial stiffness: integrative ap-
proach combining monocyte ADM expression, plasma MR-Pro-ADM, and
genome-wide association study. Circ Cardiovasc Genet 2014;7:634–641.
17. van den Borne P, Quax PH, Hoefer IE, Pasterkamp G. The multifaceted functions
of CXCL10 in cardiovascular disease. Biomed Res Int 2014;2014:893106.
18. Gomez D, Reich NC. Stimulation of primary human endothelial cell proliferation
by IFN. J Immunol 2003;170:5373–5381.
19. Condorelli G, Borello U, De Angelis L, Latronico M, Sirabella D, Coletta M, Galli
R, Balconi G, Follenzi A, Frati G, Cusella De Angelis MG, Gioglio L,
Amuchastegui S, Adorini L, Naldini L, Vescovi A, Dejana E, Cossu G.
Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac
muscle: implications for myocardium regeneration. Proc Natl Acad Sci USA 2001;
98:10733–10738.
20. Bouchentouf M, Forner KA, Cuerquis J, Michaud V, Zheng J, Paradis P, Schiffrin
EL, Galipeau J. Induction of cardiac angiogenesis requires killer cell lectin-like re-
ceptor 1 and alpha4beta7 integrin expression by NK cells. J Immunol 2010;185:
7014–7025.
21. Sobanov Y, Bernreiter A, Derdak S, Mechtcheriakova D, Schweighofer B,
Duchler M, Kalthoff F, Hofer E. A novel cluster of lectin-like receptor genes
expressed in monocytic, dendritic and endothelial cells maps close to the NK re-
ceptor genes in the human NK gene complex. Eur J Immunol 2001;31:3493–3503.
22. Marelli-Berg FM, Clement M, Mauro C, Caligiuri G. An immunologist’s guide to
CD31 function in T-cells. J Cell Sci 2013;126:2343–2352.
23. Mack JJ, Iruela-Arispe ML. NOTCH regulation of the endothelial cell phenotype.
Curr Opin Hematol 2018;25:212–218.
24. Fang JS, Coon BG, Gillis N, Chen Z, Qiu J, Chittenden TW, Burt JM, Schwartz
MA, Hirschi KK. Shear-induced Notch-Cx37-p27 axis arrests endothelial cell
cycle to enable arterial specification. Nat Commun 2017;8:2149.
25. Meens MJ, Pfenniger A, Kwak BR, Delmar M. Regulation of cardiovascular con-
nexins by mechanical forces and junctions. Cardiovasc Res 2013;99:304–314.
26. Fang JS, Angelov SN, Simon AM, Burt JM. Cx37 deletion enhances vascular
growth and facilitates ischemic limb recovery. Am J Physiol Heart Circ Physiol 2011;
301:H1872–81.
27. Bilbija D, Haugen F, Sagave J, Baysa A, Bastani N, Levy FO, Sirsjo A, Blomhoff R,
Valen G. Retinoic acid signalling is activated in the postischemic heart and may in-
fluence remodelling. PLoS One 2012;7:e44740.
28. Ahmed MS, Oie E, Vinge LE, Yndestad A, Andersen GG, Andersson Y,
Attramadal T, Attramadal H. Induction of myocardial biglycan in heart failure in
rats–an extracellular matrix component targeted by AT(1) receptor antagonism.
Cardiovasc Res 2003;60:557–568.
29. Moya IM, Umans L, Maas E, Pereira PN, Beets K, Francis A, Sents W, Robertson
EJ, Mummery CL, Huylebroeck D, Zwijsen A. Stalk cell phenotype depends on
integration of Notch and Smad1/5 signaling cascades. Dev Cell 2012;22:501–514.
30. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J,
Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M,
Gerhardt H, Betsholtz C. Dll4 signalling through Notch1 regulates formation of
tip cells during angiogenesis. Nature 2007;445:776–780.
31. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM,
Rosewell I, Busse M, Thurston G, Medvinsky A, Schulte-Merker S, Gerhardt H.
Endothelial cells dynamically compete for the tip cell position during angiogenic
sprouting. Nat Cell Biol 2010;12:943–953.
32. Barallobre-Barreiro J, Didangelos A, Schoendube FA, Drozdov I, Yin X,
Ferna´ndez-Caggiano M, Willeit P, Puntmann VO, Aldama-Lo´pez G, Shah AM,
Dome´nech N, Mayr M. Proteomics analysis of cardiac extracellular matrix
remodeling in a porcine model of ischemia/reperfusion injury. Circulation 2012;
125:789–802.
33. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling,
and functions during vascular morphogenesis and neovessel stabilization. Circ Res
2005;97:1093–1107.
34. Lomas DA, Mahadeva R. Alpha1-antitrypsin polymerization and the serpinopa-
thies: pathobiology and prospects for therapy. J Clin Invest 2002;110:1585–1590.
35. Lewis EC. Expanding the clinical indications for alpha(1)-antitrypsin therapy. Mol
Med 2012;18:957–970.
36. Toldo S, Seropian IM, Mezzaroma E, Van Tassell BW, Salloum FN, Lewis EC,
Voelkel N, Dinarello CA, Abbate A. Alpha-1 antitrypsin inhibits caspase-1 and
protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol
2011;51:244–251.
37. Daemen MARC, Heemskerk VH, van ’t Veer C, Denecker G, Wolfs TGAM,
Vandenabeele P, Buurman WA. Functional protection by acute phase proteins
a1-acid glycoprotein and a1-antitrypsin against ischemia/reperfusion injury by
preventing apoptosis and inflammation. Circulation 2000;102:1420–1426.
38. Scott RE, Ghule PN, Stein JL, Stein GS. Cell cycle gene expression networks dis-
covered using systems biology: significance in carcinogenesis. J Cell Physiol 2015;
230:2533–2542.
39. Guo L, Zhang H, Hou Y, Wei T, Liu J. Plasmalemma vesicle-associated protein: a
crucial component of vascular homeostasis. Exp Ther Med 2016;12:1639–1644.
40. He L, Huang X, Kanisicak O, Li Y, Wang Y, Li Y, Pu W, Liu Q, Zhang H, Tian X,
Zhao H, Liu X, Zhang S, Nie Y, Hu S, Miao X, Wang QD, Wang F, Chen T, Xu
Single cell transcriptome analyses of cardiac endothelial cells 2519
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..Q, Lui KO, Molkentin JD, Zhou B. Preexisting endothelial cells mediate cardiac
neovascularization after injury. J Clin Invest 2017;127:2968–2981.
41. Skelly DA, Squiers GT, McLellan MA, Bolisetty MT, Robson P, Rosenthal NA,
Pinto AR. Single-cell transcriptional profiling reveals cellular diversity and inter-
communication in the mouse heart. Cell Rep 2018;22:600–610.
42. Gladka MM, Molenaar B, de Ruiter H, van der Elst S, Tsui H, Versteeg D,
Lacraz GPA, Huibers MMH, van Oudenaarden A, van Rooij E. Single-cell
sequencing of the healthy and diseased heart reveals cytoskeleton-associated
protein 4 as a new modulator of fibroblasts activation. Circulation 2018;138:
166–180.
43. Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity.
Nat Commun 2017;8:14361.
44. Ichimura K, Stan RV, Kurihara H, Sakai T. Glomerular endothelial cells form dia-
phragms during development and pathologic conditions. J Am Soc Nephrol 2008;
19:1463–1471.
45. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR,
Zhang X, Zhang W, Walter-Yohrling J, Rouleau C, Akmaev VR, Wang CJ, Cao
X, St Martin TB, Roberts BL, Teicher BA, Klinger KW, Stan RV, Lucey B, Carson-
Walter EB, Laterra J, Walter KA. Vascular gene expression in nonneoplastic and
malignant brain. Am J Pathol 2004;165:601–608.
46. Stan RV. Endothelial stomatal and fenestral diaphragms in normal vessels and
angiogenesis. J Cell Mol Med 2007;11:621–643.
47. Strickland LA, Jubb AM, Hongo JA, Zhong F, Burwick J, Fu L, Frantz GD,
Koeppen H. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by
tumour endothelium and is upregulated by vascular endothelial growth factor-A
(VEGF). J Pathol 2005;206:466–475.
48. Khan S, Taverna F, Rohlenova K, Treps L, Geldhof V, de Rooij L, Sokol L, Pircher
A, Conradi LC, Kalucka J, Schoonjans L, Eelen G, Dewerchin M, Karakach T, Li
X, Goveia J, Carmeliet P. EndoDB: a database of endothelial cell transcriptomics
data. Nucleic Acids Res 2018;47:D736–D744.
2520 Z. Li et al.
CARDIOVASCULAR FLASHLIGHT doi:10.1093/eurheartj/ehz261Online publish-ahead-of-print 28 April 2019
....................................................................................................................................................
Endovascular rescue-stenting of a rupturedmycotic subclavian
pseudoaneurysm caused by pulmonary aspergillosis
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A 59-year-old man pre-
sented with recurring
haemoptysis. Two months
earlier, allogenic periph-
eral blood stem cell trans-
plantation had been
performed due to pro-
gressive myelodysplastic
syndrome. Thereafter, the
patient had suffered from
severe pneumonia fol-
lowed by right jugular/sub-
clavian vein thrombosis.
Diagnostic computed
tomography angiography
revealed a large (8 cm)
pseudoaneurysm (*) of
the right subclavian artery
(þ) (Panel A) with surrounding diffuse pulmonary haemorrhages but no active bleeding. Two hours later, fulminant haemoptysis spontane-
ously occurred requiring cardiopulmonary resuscitation and intubation. The patient was immediately prepared for angiography, and a
10 mm balloon-expanding ePTFE-covered stent was successfully implanted across the neck of the pseudoaneurysm sealing the haemor-
rhage (Panels B and C). Thereupon, the patient stabilized and was scheduled for subsequent aneurysm resection. Unfortunately, repeated
hypertensive crises provoked another massive pulmonary bleeding event under which the patient passed away.
Autopsy revealed a properly implanted in situ stent graft with sealing of the ruptured pseudoaneurysm (Panel D, stent removed) but signs
of a diffuse bleeding within the right upper lobe (#) with consecutive massive aspiration (Panel E). Histology displayed inflamed and necrotic
lung tissue within the right upper lobe (Panel F) with mycotic infiltrations (Panel G) and pulmonary aspergillosis was confirmed.
The primary treatment of choice in mycotic subclavian artery pseudoaneurysm is surgical resection including lobectomy. However, the
peracute rupture of the pseudoaneurysm demanded an interventional approach with rescue exclusion, which can be effectively achieved
by the usage of covered stent grafts. Nevertheless, subsequent surgical resection must be carefully evaluated as soon as possible due to the
aggressive progression of invasive pulmonary aspergillosis.
Supplementary material is available at European Heart Journal online.
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